Simulect
What Simulect is used for
Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Simulect
- Active substance
- basiliximab
- Disease area
- Graft Rejection; Kidney Transplantation
- Medicine group
- Immunosuppressants
- ATC code
- L04AC02
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 1998
Official information
In the USA
Same active substance: Simulect
In India
- Basiliximab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Simulect used for?
Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
What is the active substance in Simulect?
Simulect contains basiliximab.
Who makes Simulect?
The EU marketing authorisation holder is Novartis Europharm Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU